Agranulocytosis.
Young
N S
NS
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced* / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011719:Pyrazines; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002316:Cardiotonic Agents; D011719:Pyrazines; D011804:Quinolines; D016179:Granulocyte Colony-Stimulating Factor; C041667:vesnarinone; D016178:Granulocyte-Macrophage Colony-Stimulating Factor